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that sequential therapy with ALN and RIS after TPTD both 
improved bone mass and structure. Our results further sug-
gest that RIS may have a greater effect on improving bone 
quality and stiffness than ALN despite less prominent effect 
on BMD. Further studies are necessary to determine clini-
cal relevance of these findings to fracture rate.
Keywords Risedronate · Bone quality · Bone 
architecture · Alendronate · Teriparatide
Introduction
Teriparatide (TPTD), an N-terminal fragment of human 
parathyroid hormone (PTH) (1–34), is an anabolic agent for 
the treatment of osteoporosis [1–3] that markedly increases 
bone mineral density (BMD) and decreases fracture risk 
[4–6]. It has been shown to be even more potent particularly 
in lumbar BMD gains than standard antiresorptives such as 
alendronate (ALN) and raloxifene [7–10]. However, dura-
tion of TPTD therapy is restricted to 2 years during lifetime 
due to a concern about development of osteosarcoma [11, 
12]. Moreover, discontinuation of TPTD treatment results 
in substantial loss of the BMD gains by the drug. It is thus 
recommended to sequentially use antiresorptives following 
TPTD therapy to maintain bone mass [4, 13, 14].
Several studies have investigated efficacy of concur-
rent or sequential treatment with TPTD and antiresorptives 
including bisphosphonates [15–23]. Contrary to an ini-
tial expectation that simultaneous treatment with anabolic 
and antiresorptive agents would result in a greater BMD 
increase in an additive or synergistic manner, a combina-
tion therapy of TPTD and ALN turned out to be less effica-
cious than TPTD monotherapy [16]. Sequential treatment 
with TPTD after antiresorptives also resulted in diminished 
Abstract Teriparatide (TPTD), a recombinant human 
parathyroid hormone N-terminal fragment (1–34), is a 
widely used bone anabolic drug for osteoporosis. Sequen-
tial treatment with antiresorptives such as bisphosphonates 
after TPTD discontinuation is generally recommended. 
However, relative effects of bisphosphonates have not been 
determined. In the present study, we directly compared 
effects of risedronate (RIS) and alendronate (ALN) on bone 
mineral density (BMD), bone turnover, structural property 
and strength in ovariectomized (OVX) rats, when admin-
istered after TPTD. Female Sprague Dawley rats were 
divided into one sham-operated and eight ovariectomized 
groups. TPTD, RIS, and ALN were given subcutaneously 
twice per week for 4 or 8 weeks after 4 week treatment 
with TPTD. TPTD significantly increased BMD (+9.6%) in 
OVX rats after 4 weeks of treatment. 8 weeks after TPTD 
withdrawal, vehicle-treated group showed a blunted BMD 
increase of +8.4% from the baseline. In contrast, 8 weeks of 
treatment with RIS and ALN significantly increased BMD 
to 17.4 and 21.8%, respectively. While ALN caused a con-
sistently larger increase in BMD, sequential treatment with 
RIS resulted in lower Tb.Sp compared to ALN in the fourth 
lumbar vertebra as well as in greater stiffness in compres-
sion test. In conclusion, the present study demonstrated 
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effects. The blunted response to TPTD by concomitant or 
prior treatment with antiresorptives seemed in part due to 
the fact that the anabolic effect of TPTD depends on bone 
remodeling activity [23–26]. Exceptionally, however, zole-
dronate and denosumab showed additive effect when used 
in combination with TPTD [9, 27] despite their strong 
antiresorptive activities. Thus, the mechanism of bone ana-
bolic effects of TPTD and its interactions with antiresorp-
tive agents remain to be elucidated.
Risedronate (RIS) and ALN are nitrogen-containing 
bisphosphonates widely used as first-line drugs for the 
treatment of osteoporosis. Although these two bisphos-
phonates share the fundamental mechanism of inhibiting 
bone resorption [28], they significantly differ in potency of 
inhibiting farnesyl pyrophosphate synthase and affinity to 
hydroxyapatite [29]. Such unique properties may explain 
differences in clinical efficacy of the two bisphosphonates; 
despite its less prominent effect on bone turnover and BMD 
than ALN, RIS appears similarly to or even more effective 
in preventing hip and non-vertebral fractures during the 
first year of therapy [30] and in experimental animals as 
well under certain conditions [31]. As for sequential ther-
apy, 1-year TPTD therapy after prior treatment with RIS 
or ALN for at least 2 years significantly increased BMD 
and bone formation markers, and the effect was greater 
in patients previously treated with RIS than in those pre-
treated with ALN [22]. It is also of note that a combina-
tion therapy with RIS and TPTD caused a greater effect 
than monotherapy in humans [32, 33]. In rodents, sequen-
tial treatment with RIS was able to maintain BMD gains by 
PTH pretreatment in ovariectomized (OVX) animals [34]. 
Similar results were obtained with ALN when administered 
after TPTD in rats [35]. It is currently unknown whether 
effects of sequential treatment with bisphosphonates after 
TPTD therapy differ among different bisphosphonates.
Thus, in the present study, effects of sequential treatment 
with RIS and ALN after TPTD therapy were directly com-
pared in OVX rats.
Materials and Methods
Experimental Animals
Seventy two female Sprague–Dawley (SD) rats at 7 weeks 
of age were used (Beijing Vital River, Beijing, China). The 
animals were housed two per cage in a room with light/dark 
cycle of 12/12  h and were acclimated to study condition 
for 5 weeks prior to the start of the experiment. All ani-
mals were pair-fed rodent food (irradiated, Shanghai SLAC 
Laboratory Animal Co. Ltd., Shanghai, China). Water from 
PharmaLegacy Laboratories Co. Ltd. (Shanghai, China) in 
house production was available to animals ad libitum. The 
experimental protocols were approved by Animal Care and 
Use Committee of EA Pharma Co. Ltd. and PharmaLegacy 
Laboratories IACUC.
Materials
Risedronate (cat no. R521500) was purchased from 
Toronto Research Chemical (Toronto, ON, Canada). 
Alendronate (cat no. 126855) and teriparatide (cat no. 
05235501) were purchased from EMD Biosciences (Darm-
stadt, Germany). Atropine (cat no. A0132), calcein (cat 
no. C0875), buprenorphine (cat no. B9275), gentamicin 
(cat no. G1914), and ketamine (cat no. K2753) were pur-
chased from Sigma (St. Louis, MO, USA). Isoflurane (cat 
no. 1001936040) was purchased from Baxter (Deerfield, 
IL, USA).
Experimental Design
The experimental timeline is summarized in Fig.  1. The 
animals were assigned to sham-operated or ovariectomized 
(OVX) group by matching body weight and bone min-
eral density (BMD) of lumbar vertebrae (L2-L5) by Bio-
Book system (IDBS, ID Business Solutions LTD., Shang-
hai, China). The OVX group was assigned to (1) vehicle, 
(2) TPTD, (3) TPTD and vehicle, (4) TPTD and RIS, (5) 
TPTD and ALN, (6) TPTD and vehicle, (7) TPTD and 
RIS, and (8) TPTD and ALN with eight animals in each 
group. The groups (1) and (2) were sacrificed at 4 weeks; 
(3), (4), and (5) were at 8 weeks; and (6), (7), (8), and the 
sham groups were at 12 weeks. TPTD (0.1 mg/kg, s.c.) was 
injected twice a week for 4 weeks. RIS (0.01 mg/kg, s.c.) or 
ALN (0.02 mg/kg, s.c.) was injected twice a week for 4 or 
8 weeks after TPTD (Fig. 1).
Atropine (0.05 mg/kg, s.c.) was injected before surgery. 
Under anesthesia with ketamine (70  mg/kg, i.p.) and iso-
flurane 1–5% inhalation with a 0.8–1.5 L flow rate of oxy-
gen, the animals were removed of the bilateral ovaries or 
sham-operated from a low abdominal approach. Animals 
received analgesics including but not limited to buprenor-
phine (0.05 mg/kg, i.m.) and gentamycin (20 mg/kg, i.m.) 
after surgery.
Four, 8, and 12 weeks after dosing, the animals were 
evaluated for BMD of lumbar vertebrae (L2-L5) by in vivo 
Dual-Energy X-ray Absorptiometry (DEXA, Hologic Dis-
covery SL; Hologic, Inc., Waltham, MA, USA). After sac-
rifice at the end of each treatment protocol, BMD of the 
fourth lumbar vertebra was measured ex vivo by peripheral 
Dual-Energy X-ray Absorptiometry (pDEXA, Norland/
Stratec, Pforzheim, Germany). They were also subjected 
to mechanical testing (L5) and histomorphometric analysis 
(L4).
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Labeling and Histomorphometry
Fluorochrome dye of calcein was administered to quan-
tify bone formation rates. Calcein (10  mg/kg, s.c.) was 
administered at 9 and 2 days prior to sacrifice. The L4 
were collected and prepared by undecalcifying methods. 
The specimens were dehydrated through gradient etha-
nol and embedded in methyl methacrylate. The blocks 
were sectioned at about 5  μm in thickness for staining 
and histomorphometry. Static and dynamic histomorpho-
metric analyses of the L4 were performed. One section 
was stained with Goldner’s trichrome for static parameter 
measurements, and another was kept unstained for dynamic 
parameter measurements. The histomorphometry was done 
using OsteoMeasure™ (OsteoMetrics, Inc., Decatur, GA) 
software program on a computer in conjunction with a 
Nikon E501 bright field and fluorescent microscope (Nikon 
Corporation, Tokyo, Japan) to measure the primary param-
eters: bone surface (BS, µm), osteoclast surface (Oc.S, μm), 
osteoclast number (N.Oc), osteoid surface (OS, μm), oste-
oblast surface (Ob.S, μm), and mineralizing surface (MS, 
μm). The following parameters were calculated from pri-
mary parameters: osteoid surface (OS/BS, %), number of 
osteoclasts per trabecular surface (N.Oc/BS, /mm), surface 
area of osteoclasts contacting the trabecular surface (Oc.S/
BS, %), osteoblast surface (Ob.S/BS, %), mineralized sur-
face (MS/BS, %), bone formation rate (BFR/BS, %/year), 
and mineral apposition rate (MAR, μm/day). Osteoclasts 
were identified as cells forming resorption lacunae at the 
bone surface. Structural indices were measured by these 
systems: bone volume (BV/TV, %), trabecular thickness 
(Tb.Th, μm), trabecular number (Tb.N, /mm), and trabecu-
lar separation (Tb.Sp, μm) [36].
Mechanical Testing
The fifth lumbar vertebrae (L5) and femurs were tested 
for bone strength by compression and three-point bend-
ing tests, respectively, using previously described meth-
ods with a slight modification [37]. The biomechanical 
testing was done using MTS858 (MTS System, Minneap-
olis, MN). For compression tests, the vertebra was fixed 
on a holder with adhesive agent and placed on the test-
ing platform. For three-point bending of femur, the span 
of the two support points below the bone was 14  mm. 
The deformation rate was 6 mm/min for both femurs and 
vertebrae.
Load-deformation curves were transported to a per-
sonal computer and acquired by Team 490 software (ver-
sion 4.10, Nicolet Instrument Technologies, Madison, 
WI). Sigma Plot 7.0 software (SPSS, Chicago, IL) was 
used to smooth the load-deformation curve and calculate 
the extrinsic material properties of the bone samples, 
including the maximal load (N) and linear stiffness (N/
mm).
Statistical Analysis
All data were expressed as mean ± standard deviation (SD). 
According to the results of Shapiro–Wilk test for normal 
distribution, group differences were analyzed by t-test or 
Wilcoxon test and analysis of variance (ANOVA) with post 
hoc Dunnett’s test or Steel test on JMP (ver. 12.0.1, SAS 
Institute, Tokyo, Japan), and two-way ANOVA on Prism 
(ver. 6.07, Graph Pad Software, .CA, USA). P values less 
than 0.05 were considered statistically significant.
Fig. 1  Study timeline. Treat-
ment was started from the next 
day after surgery. Animals 
were treated with vehicle or 
teriparatide (TPTD) twice a 
week for 4 weeks. After TPTD 
withdrawal, vehicle, risedronate 
(RIS), or alendronate (ALN) 
were given subcutaneously for 
4 or 8 weeks. BMD, bone archi-
tecture, and bone strength was 
measured at 4, 8, or 12 weeks 
after surgery
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Results
In Vivo BMD of L2‑L5 by DEXA
As shown in Fig.  2, the sham-operated rats gradually 
gained BMD throughout the study: 13.2, 15.8, and 18.6% at 
4, 8, and 12 weeks, respectively. The vehicle-treated OVX 
rats only showed a 2.4% increase in BMD during the ini-
tial 4 weeks. In contrast, the TPTD-treated rats showed a 
significantly greater increase in BMD at 4 weeks (9.6%, 
p < 0.0002, compared with vehicle). After discontinuation 
of TPTD, the subsequent treatment with vehicle caused a 
gradual decline in BMD during 4–12 weeks. In sharp con-
trast, the rats sequentially treated with ALN or RIS follow-
ing TPTD therapy attained the BMD level similar to the 
sham-operated animals and significantly higher than the 
TPTD vehicle-treated OVX rats at 12 weeks. At 8 weeks, 
only the TPTD-ALN group, showed a significantly higher 
BMD than that of TPTD-vehicle rats, suggesting that effect 
of ALN on BMD might be somewhat superior to that of 
RIS at the early phase of sequential treatment after TPTD.
Ex Vivo BMD of L4 and Tibia by pDEXA
As shown in Fig. 3, ex vivo BMD scans by pDEXA gave 
similar results to those obtained by in  vivo DEXA. Dur-
ing the first 4 weeks, TPTD significantly increased BMD 
compared with vehicle. After TPTD discontinuation, 
sequential treatment with either ALN or RIS resulted in a 
greater increase in L4 BMD compared with vehicle at 12 
weeks. However, at 8 weeks, significant difference from 
the vehicle was only observed with ALN. And BMD at 12 
weeks was significantly higher in TPTD-ALN rats than that 
in the TPTD-RIS group (Fig.  3). Thus, at least effect on 
lumbar BMD appeared greater with ALN than RIS when 
used in sequential therapy after TPTD.
We also analyzed right tibia BMD and obtained virtu-
ally the same results: both ALN and RIS caused signifi-
cantly greater increases than vehicle at 12 weeks, but ALN 
showed a slightly greater effect (data not shown).
Mechanical Testing
Vertebral compression tests revealed that treatment with 
TPTD for 4 weeks caused no significant changes in stiff-
ness (Fig.  4a). And sequential therapy with RIS did not 
significantly affect vertebral stiffness at 8 and 12 weeks, 
either. Interestingly, although ALN-treated rats showed 
higher BMD at 12 weeks, stiffness was significantly lower 
compared with RIS (Fig. 4a). As for maximum load, initial 
Fig. 2  Effect of sequential treatment with bisphosphonates after teri-
paratide on lumber vertebral BMD (L2-L5). Sham-operated rats are 
shown in open circles. Ovariectomized rats treated with vehicle for 
4 weeks are shown in open squares. The other rats were first treated 
with teriparatide for 4 weeks, and then with vehicle (closed circles), 
risedronate (closed triangles), or alendronate (closed rhombuses) for 
up to 8 weeks. Percent increases from the baseline in lumber vertebral 
BMD (L2-L5), measured by in vivo DEXA are shown in mean ± SD. 
At 4 weeks, sham and vehicle: n = 8 and TPTD: n = 56. At 8 weeks, 
sham: n = 8 and TPTD→vehicle, TPTD→RIS, and TPTD→ALN: 
n = 16. At 12 weeks, sham, TPTD→vehicle, TPTD→RIS, and 
TPTD→ALN: n = 8. ***p < 0.001 and ****p < 0.0001 compared with 
the vehicle-treated group at the same time point
Fig. 3  Effect of sequential treatment with bisphosphonates after teri-
paratide on lumbar vertebral BMD (L4). After ovariectomy, rats were 
treated with vehicle or teriparatide for 4 weeks. After teriparatide 
withdrawal, risedronate or alendronate was given for another 4 or 8 
weeks. Lumber vertebrae were harvested from the rats at 4, 8, or 12 
weeks for ex vivo BMD measurements by pDEXA. Values of lumbar 
vertebral BMD (L4) are shown in mean ± SD. n = 8. **p < 0.01 and 
****p < 0.0001 compared with the vehicle-treated group at same time 
point. cp < 0.001 significant difference between risedronate and alen-
dronate
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treatment with TPTD and a subsequent treatment with RIS 
and ALN resulted in no appreciable changes compared to 
vehicle at each time point (Fig.  4b). Three-point bending 
tests revealed no statistically significant effects of these 
drugs on femoral strength (Table 1).
Histomorphometry of Lumbar Vertebrae
As shown in Table 2, histomorphometric analysis of lum-
bar vertebrae revealed that Ob.S/BS, OS/BS, BFR/BS, and 
MS/BS were significantly increased by TPTD compared 
with vehicle at 4 weeks, confirming enhanced bone for-
mation. And at 8 and 12 weeks, discontinuation of TPTD 
caused a significant decrease in these parameters.
Both RIS and ALN, administered after TPTD, sig-
nificantly reduced parameters of bone turnover such 
as N.OC/BS, Ob.S/BS, and BFR/BS. As a result, these 
bisphosphonates improved bone volume and structural 
indices at 8 and 12 weeks, and a significant decrease 
was observed in Tb.Sp. Interestingly, RIS showed a sig-
nificantly lower Tb.Sp compared with ALN at 12 weeks 
(Table  2). We also obtained similar results in the histo-
morphometric analysis of proximal tibia. Both bisphos-
phonates significantly suppressed turnover indices such as 
BFR/BS and increased BV/TV and structural parameters 
(data not shown). Tb.Sp at 12 weeks was lower in RIS 
compared with ALN: 569 ± 257, 209 ± 42, and 235 ± 58 
μm in vehicle, RIS, and ALN, respectively. Thus, supe-
rior effect of RIS on trabecular quality appeared repro-
ducible in two different types of bones.
Discussion
Duration of TPTD treatment is limited to 2 years in clini-
cal practice [12]. And TPTD effect seems at least in part 
Fig. 4  Effect of sequential treatment with bisphosphonates after teri-
paratide on a stiffness and b maximum load of lumber vertebra (L5). 
After ovariectomy, rats were treated with vehicle or teriparatide for 
4 weeks. After teriparatide withdrawal, risedronate or alendronate 
was given for another 4 or 8 weeks. Lumber vertebrae (L5) were har-
vested from the rats at 4, 8, or 12 weeks and subjected to compres-
sion tests. Data are mean ± SD. n = 8. *p < 0.05 significant difference 
between risedronate and alendronate
Table 1  Effects of sequential treatment with bisphosphonates after teriparatide on femoral bone strength in ovariectomized rats
After ovariectomy, rats were first treated with vehicle or teriparatide for 4 weeks, and then with vehicle, risedronate, or alendronate for another 4 
or 8 weeks. After sacrifice, the right femur was obtained, cleaned of soft tissue, and tested for bone strength by three-point bending
Data are mean ± SD n = 8
4 weeks 8 weeks 12 weeks
Vehicle Teriparatide Vehicle Risedronate Alendronate Vehicle Risedronate Alendronate Sham
Stiffness (N/
mm)
502.4 ± 43.0 490.2 ± 26.9 541.8 ± 47.9 575.3 ± 61.0 533.5 ± 53.2 575.0 ± 63.9 565.1 ± 76.8 567.8 ± 61.5 604.1 ± 32.9
Maximum load 
(N)
155.6 ± 16.6 157.0 ± 12.0 163.5 ± 10.0 172.9 ± 16.2 167.1 ± 10.4 172.0 ± 17.6 172.3 ± 12.3 173.7 ± 13.3 179.3 ± 13.1
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reversible because discontinuation of TPTD results in sig-
nificant bone loss. Thus, it is important and generally rec-
ommended for clinicians to sequentially treat patients with 
antiresorptives after TPTD therapy. There is, however, lit-
tle evidence available for selection of specific post-TPTD 
therapy. Given the lack of such evidence, particularly, for 
bisphosphonates, we directly compared effects of two most 
commonly prescribed oral bisphosphonates, RIS and ALN, 
as a post-TPTD sequential therapy in OVX rats. The results 
demonstrated that both bisphosphonates were effective in 
terms of bone turnover suppression, BMD increase, and 
improvement of structural properties. As for the difference 
between the two bisphosphonates, ALN seemed stronger 
in turnover suppression and BMD increase, whereas RIS 
exhibited partially greater improvement in microstructure 
and strength.
In the current experiments, we adopted the same ratio of 
RIS and ALN doses as that clinically used (1:2). Although 
we do not have sufficient evidence or rationale for such 
a protocol in rodents, we were indeed able to observe 
some differences between RIS and ALN under such an 
experimental condition. First, BMD measurements by 
either in vivo DEXA or ex vivo pDEXA revealed greater 
effect of ALN than RIS in increasing BMD after TPTD 
therapy. This is consistent with the fact that in regular clini-
cal doses, ALN showed a greater efficacy than RIS both in 
terms of turnover suppression and BMD gains in human 
subjects [38].
Contrary to a simple assumption that such BMD gains 
result in improved bone strength, the more robust incre-
ment in BMD by ALN did not translate into better mechan-
ical properties compared with RIS. In fact, 8 weeks of 
treatment with RIS after 4-week TPTD treatment resulted 
in better stiffness in the compression test despite the lower 
BMD at the same time point, compared to TPTD-ALN 
sequential treatment. We are well aware that the results may 
not be definitively conclusive considering significant vari-
ations in such mechanical tests. Importantly, however, we 
were also able to demonstrate significantly lower trabecular 
separation at the histological level in RIS-treated rats. And 
the analyses of the bones in two distinct sites, vertebrae 
and proximal tibiae, showed consistent results. Thus, we 
Table 2  Histomorphometric analysis of vertebra (L4) in ovariectomized rats sequentially treated with bisphosphonates after teriparatide
After ovariectomy, rats were first treated with vehicle or teriparatide for 4 weeks, and then with vehicle, risedronate, or alendronate for another 4 
or 8 weeks. After sacrifice, the 4th lumbar vertebra was removed free of soft tissue, processed, and analyzed for static and dynamic histomorpho-
metric parameters
* p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 compared with the vehicle-treated group at same time point. $$p < 0.01 and $$$$p < 0.0001 
compared with risedronate at 8 or 12 weeks. #p < 0.05 compared with Sham group at 12 weeks. Data are mean ± SD. n = 8
4 weeks 8 weeks 12 weeks
Vehicle Teriparatide Vehicle Risedronate Alendronate Vehicle Risedronate Alendronate Sham
BV/TV 
(%)
24.42 ± 5.92 21.93 ± 4.35 21.19 ± 5.19 22.52 ± 6.80 24.15 ± 3.36 19.43 ± 4.14 25.24 ± 4.34 22.36 ± 5.24 23.32 ± 7.05
Tb.Th 
(μm)




3.54 ± 0.54 3.24 ± 0.41 2.90 ± 0.37 3.21 ± 0.68 3.28 ± 0.30 2.95 ± 0.47 3.27 ± 0.42 2.95 ± 0.42 3.54 ± 0.82
Tb.Sp 
(μm)





0.18 ± 0.09 0.19 ± 0.14 0.20 ± 0.12 0.06 ± 0.04 0.08 ± 0.07 0.24 ± 0.16 0.07 ± 0.04** 0.10 ± 0.05* 0.35 ± 0.11
Oc.S/BS 
(%)




2.58 ± 0.57 4.85 ± 2.12* 1.57 ± 2.00 0.26 ± 0.21 0.22 ± 0.11 1.35 ± 1.07#, $$ 0.25 ± 0.21** 0.21 ± 0.15** 0.34 ± 0.21
OS/BS 
(%)
1.76 ± 0.54 5.06 ± 1.45** 2.01 ± 2.05 0.81 ± 0.55 0.54 ± 0.42 2.23 ± 2.68 0.14 ± 0.10** 0.20 ± 0.16** 0.48 ± 0.44
MS/BS 
(%)
28.24 ± 4.50 37.36 ± 5.85** 18.33 ± 6.08$$$$ 12.07 ± 3.12* 12.16 ± 3.55* 21.32 ± 5.22 
#, $$$$








1.19 ± 0.16 1.12 ± 0.14 0.92 ± 0.21 0.71 ± 0.11 059 ± 0.25* 0.78 ± 0.09$$ 045 ± 0.49 053 ± 0.45 088 ± 0.13
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believe that the results are suggestive of preferential effect 
of RIS on structural properties independent of BMD.
Although the mechanism is unknown, potentially supe-
rior effect of RIS on bone quality has already been recog-
nized: clinical data have suggested that RIS appears more 
effective than ALN in preventing hip and non-vertebral 
fractures during the first year of therapy. Although no direct 
comparison has been made prospectively, RIS-treated sub-
jects have a lower incidence of hip fractures than those 
treated with ALN for 12 months (0.37 vs. 0.58%) [30]. RIS 
is known to have less affinity to hydroxyapatite and more 
potency in inhibiting farnesyl pyrophosphate synthase than 
ALN. Such differences have been hypothesized to cause 
distinct distribution pattern and local effects. For exam-
ple, a previous study demonstrated deeper penetration of 
RIS into the bone tissue compared to ALN [39]. And we 
have indeed demonstrated actual differences in the effects 
of RIS and ALN on micro architecture in calcium-deficient 
OVX rats [31]. Thus, in the context of post-TPTD therapy, 
it seems plausible that RIS exhibited a distinct effect from 
ALN on bone microstructure, most likely with complex 
interaction with residual effect of prior TPTD treatment.
There are limitations in this study. First, morphological 
analysis was only done with classical histomorphometry 
[40], as we were unable to analyze the bone with micro 
CT that has widely been used in recent years. Another 
limitation is that we used younger rats at 12 weeks of age 
compared to previous studies [34]. Our results should be 
interpreted with caution and may not be applied to older 
animals.
Conclusions
In conclusion, we demonstrated that both RIS and ALN 
suppressed bone turnover, increased BMD, and improved 
structural properties in OVX rats when used for sequential 
treatment after TPTD. And we also found for the first time 
by direct comparison that ALN caused a stronger suppres-
sion of bone turnover and a more robust increase in BMD, 
whereas RIS treatment resulted in potentially better tra-
becular architecture and stiffness, suggesting preferential 
effect of RIS on bone quality. Whether such differences are 
indeed clinically relevant awaits fracture prevention stud-
ies by sequential treatment with different bisphosphonates 
after TPTD.
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